跳至主要内容
临床试验/EUCTR2018-003616-49-FI
EUCTR2018-003616-49-FI进行中(未招募)1 期

The effect of seasonal prophylactic influenza vaccination and factors influencing the patients' immune-competence during anti-PD-1 treatment of patients with melanoma

Finnish Melanoma Group0 个研究点目标入组 90 人开始时间: 2018年10月30日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Melanoma patients on anti-PD1 antibody therapy, aged >18 years, written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 70
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • Any confirmed / suspected immunosuppressive/ immunodeficient condition, including HIV-infection, administration (>14 days) of immunosupressive or immune-modifying drugs within 6 months before vaccination, i.e. oral corticosteroids (Prednisolone > or = 20 mg/ day or equivalent). Inhaled or topical steroids are permitted. Pregnancy or lactation. Acute infection at the time of the enrolment. Contraindication for innfluenza vaccination

研究者

发起方
Finnish Melanoma Group

相似试验